on Baloise Holding AG (isin : CH0012410517)
Charles Ischi AG Wins InnoPrix SO! Award for Pharmaceutical Innovation
Charles Ischi AG, a Swiss company known for creating testing devices for tablets and capsules, has been awarded the 2024 InnoPrix SO! for its DISI Evo disintegration tester. This innovative device is designed to accurately measure the breakdown time of medications, a critical factor for ensuring drug efficacy. The tester is particularly beneficial for analyzing complex delayed-release tablets that contain multiple active ingredients.
The DISI Evo stands out for its ability to test a wide range of products, including hard and soft capsules, mini tablets, and even the smallest doses with micro-discs. Its user-friendly design suits modern laboratories aiming for efficiency. This technological advancement was developed in collaboration with regional partners, highlighting Solothurn's innovative capacity and Switzerland's status as a leading technology hub.
Recognized for its maturity and broad applicability, the innovation won Charles Ischi AG a prize of CHF 25,000. The annual InnoPrix SO!, presented by Baloise Bank Ltd's foundation since 1987, encourages projects that stimulate the Solothurn economy.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Baloise Holding AG news